Survey of Tau Partners Highlights Synaptic, Mitochondrial Roles
An unbiased “interactome” generated from human neurons could shed light on what goes wrong in tauopathies, and help identify new therapeutic targets.
ALL NEWS
6066 RESULTS
Sort By:
- Most Recent
- Most Commented
Proteomics Highlight Alzheimer’s Changes in Matrisome, MAPK Signaling
Protein networks unseen in RNA data correlated closely with plaques, tangles, cognitive decline. Many are in the extracellular matrix.
Mild COVID Infection Can Shrink Brain, Speed Cognitive Decline
In some people who had weathered COVID at home, olfactory regions in the brain shrank and executive function slowed. Will these changes resolve or persist?
Surprise! TMEM106b Fibrils Found in Neurodegenerative Diseases
In a game changer for the field, three papers report similar structures for TMEM106b fibrils. One claims they comprise the lion’s share of TDP-43 aggregates.
The Alzheimer's Vaccination Story, Continued
Two papers advance the drive to develop an Alzheimer's vaccine, one looking at the antibody response in some of the Elan trial participants, the other using sophisticated methods to analyze the epitope recognized by antibodies generated in response to Aβ42 immunization.
Varicose Axons: Traffic Jams Precede AD Pathology in Mice, Men
Early in the course of Alzheimer disease, blockages in axonal traffic lead to sick axons swollen with the jumbled pile-up of traffic components. The blockages precede...
Cannabinoid Receptors and AD: Searching Beyond the Simple Story
Researchers from Spain describe changes in cannabinoid receptors in the brains of AD patients, as well as...
AMPA Receptors: Going, Going, Gone in Aβ-exposed Synapses, PSD95 Knockouts
One of the earliest signs of amyloid-β (Aβ) toxicity is synaptic loss, and recent work from a number of labs has shown that...
Philadelphia: All Is Not Well with the Statin Story
One of the field’s biggest hopes for a quick and easy new AD therapy received a punch in the stomach today...
Statins and AD—What Role Isoprenoids?
There has been considerable excitement generated by findings that statins, which lower plasma cholesterol, may help protect against Alzheimer disease...
AD Clinical Pipeline: Immunotherapy Woes, Dimebon Boons
Two papers in the 19 July Lancet bring both dismay and hope to the ongoing quest for more effective AD treatments...
Keystone: Death Receptor Ligand—New Role for APP, New Model for AD?
At the Keystone symposium on Wednesday, debate on the last plenary talk continued around the dinner table and well into the poster session...
Genetic Testing a Foggy Crystal Ball at Best?
Sequencing a person’s entire genome will foretell many diseases only marginally better than gazing into a crystal ball...
CTAD: New Data on Sola, Bapi, Spark Theragnostics Debate
The 5th Clinical Trials in Alzheimer’s Disease conference offered new data from ongoing analyses of the Phase 3 programs on solanezumab and bapineuzumab...
Early Intervention Trial Bears Little Fruit, but Sows Hope
Is the glass half empty or half full? Alzheimer disease clinicians might be asking themselves that question after seeing the long-awaited results of...
Current Filters
No filters selected